Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir

被引:66
作者
Culm-Merdek, KE
von Moltke, LL
Gan, L
Horan, KA
Reynolds, R
Harmatz, JS
Court, MH
Greenblatt, DJ
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Boston, MA USA
关键词
D O I
10.1016/j.clpt.2005.11.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives. Acute ingestion of usual quantities of grapefruit juice produces inhibition of enteric cytochrome P450 (CYP) 3A enzymes, causing pharmacokinetic interactions with a number of drugs. However, the effect of extended exposure to grapefruit juice on CYP3A activity is not established. Methods. Triazolam, a CYP3A index compound, was administered to 3 cohorts of volunteers (n = 6-7 per group) on 4 occasions (trials 1-4), as follows: 1 day prior to cotreatment initiation, at the beginning and end of cotreatment, and 3 days after cotreatment discontinuation. The 3 cotreatments (daily administration for 10 consecutive days) were: 300 mL grapefruit juice, 400 mg ritonavir, or 300 mL water. Results: Grapefruit juice cotreatment (trial 2) increased the triazolam area under the plasma concentration curve by 50% compared to the trial 1 control (15.1 +/- 7.6 ng/mL.h versus 10.0 +/- 3.5 ng/mL.h, P < .05), but the half-life was not changed. Effects of acute and extended exposure to grapefruit juice (trials 2 and 3) were similar, and produced augmentation in benzodiazepine agonist effects measured by the Digit Symbol Substitution Test and electroencephalographic beta amplitude. Kinetic and dynamic effects reverted to baseline (trial 1) values at 3 days after grapefruit juice discontinuation (trial 4). Ritonavir caused a more than 20-fold increase in the triazolam area under the plasma concentration curve during trial 2 (553 +/- 422 ng/mL.h) and trial 3 (287 +/- 299 ng/mL.h) compared to the trial 1 control (13.3 +/- 16.3 ng/mL. h) (P < .05 for both comparisons); Digit Symbol Substitution Test and electroencephalographic pharmacodynamics increased in parallel. During trial 4, triazolam kinetics reverted close to trial 1 values, with no evidence of induction. Triazolam kinetics were not altered by water cotreatment. Conclusion: Acute and extended exposure to grapefruit juice produces quantitatively similar inhibition of enteric, but not hepatic, CYP3A. Recovery is complete within 3 days after grapefruit juice discontinuation. Ritonavir greatly inhibits both enteric and hepatic CYP3A. With extended exposure to ritonavir, inhibition is the predominant effect, and recovery to baseline is nearly complete 3 days after ritonavir discontinuation.
引用
收藏
页码:243 / 254
页数:12
相关论文
共 55 条
[1]   Drug interactions with grapefruit juice [J].
Ameer, B ;
Weintraub, RA .
CLINICAL PHARMACOKINETICS, 1997, 33 (02) :103-121
[2]   Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam [J].
Backman, JT ;
Wang, JS ;
Wen, X ;
Kivistö, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :401-407
[3]  
BAILEY DG, 1989, CLIN INVEST MED, V12, P357
[4]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[5]   Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients [J].
Bailey, DG ;
Dresser, GR ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :468-477
[6]   6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice:: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein [J].
Edwards, DJ ;
Fitzsimmons, ME ;
Schuetz, EG ;
Yasuda, K ;
Ducharme, MP ;
Warbasse, LH ;
Woster, PM ;
Schuetz, JD ;
Watkins, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) :237-244
[7]  
Edwards DJ, 1996, DRUG METAB DISPOS, V24, P1287
[8]   Time response of cytochrome P450 1A2 activity on cessation of heavy smoking [J].
Faber, MS ;
Fuhr, U .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :178-184
[9]   Drug interactions with grapefruit juice - Extent, probable mechanism and clinical relevance [J].
Fuhr, U .
DRUG SAFETY, 1998, 18 (04) :251-272
[10]   Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction [J].
Fukuda, K ;
Guo, LQ ;
Ohashi, N ;
Yoshikawa, M ;
Yamazoe, Y .
JOURNAL OF CHROMATOGRAPHY B, 2000, 741 (02) :195-203